- Global News Feed
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Cell Medicine
- Cell Therapy
- Gene therapy
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
Category Archives: Alabama Stem Cells
Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision – Stockhead
Posted: July 6, 2020 at 9:46 am
The worlds biggest listed pure-play stem cell developer has a busy slate of clinical work, notably in therapies for advanced heart failure, chronic back pain and graft-versus-host disease (GvHD).
Now these programs are approaching a thrilling denouement and, as the Demtel man enthused, theres more: Mesoblast (ASX:MSB) is also undertaking an expanded coronavirus trial after a 12-patient effort showed promising results in treating acute respiratory distress syndrome (Ards), the usual cause of death with COVID-19.
The patients received infusions of Mesoblasts allogeneic (off the shelf) mesenchymal stem cell candidate, remestemcel-L, acquired from Osiris for $106m in 2013.
Meanwhile, results from two phase III trials are expected this (September) quarter: a 566-patient effort for chronic heart failure and a 404-patient trial for chronic lower back pain caused by disc degeneration.
And in September, the US Food and Drug Administration will rule on whether or not the company can market its GvHD therapy on American shores.
Mesoblast founder and CEO Prof Silviu Itescu notes that across all its therapies the company is targeting the most severe cases where alternative therapies dont exist.
Mesoblasts proprietary process selects precursor and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell kitty is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast is targeting a common market across all its disease indications: inflammation. In the case of heart disease, tissue macrophages (cells) churn out inflammatory factors that damage heart muscle and cause fibrosis and vascular dysfunction.
The stem cells respond to severe inflammation by switching the culprit macrophages off and converting them to nice cells that actually protect the heart muscle.
This is the central mechanism in each of our disease states: heart failure, back pain, GvHD and rheumatoid arthritis, Professor Itescu says. We have the potential to make a big difference in some very big disease states where inflammation is central.
Backed by the Pratt familys listed investment vehicle Thorney Investments, Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5bn in 2011 before suffering a reality check.
Culprits included a phase II heart trial that failed to meet primary endpoints, a badly executed Nasdaq listing and Israel pharma house Teva Pharmaceuticals decision to walk away from a heart program partnership in 2016.
Mesoblast dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The companys Ards and GvHD programs are based on mesenchymal stem cell assets acquired from US pharma group Osiris Therapeutics in October 2013.
Mesoblasts own-developed cells are called mesenchymal precursor cells and they are being developed for rheumatoid arthritis and diabetic nephropathy, as well as the aforementioned heart failure and lower back pain programs.
Ards is bought on by an excessive immune response to the virus in the lungs. The immune cells produce inflammatory cytokines, which destroy lung tissue and can also damage the liver, kidney and heart.
Remestemcell-L has the potential to tame the cytokine storm in Ards and may offer a life-saving treatment for those unfortunate individual sufferers of COVID-19 Ards, Professor Itescu says.
Mesoblasts COVID-19 proclamations have been coming so thick and fast that its been Ard(s) just to keep up. But the core excitement cluster was around Mesoblasts April 23 disclosure of the results of the trial at New Yorks Mt Sinai Hospital, covering moderate to acute Ards cases.
Under the compassionate use protocol, the patients were treated with two infusions of remestemcel-L over the first five days.
The results? Nine of the 12 patients came off a ventilator within a median 10 days, with 83 per cent survival (the Grim Reapers spin on this is that two of them died).
In comparison, only 9 per cent of patients at one reference hospital (38 out of 445 patients) were able to come off the ventilator with standard-of-care treatment.
Another US hospital reported that only 38 patients of 320 or 12 per cent survived.
Of course, 12 people good and true are adequate numbers for a jury, but sub-optimal to comprise a statistically significant trial.
Thus, the company is enrolling 300 patients in a phase III, randomised, controlled trial of severe Ards patients at 30 sites.
The first patients were dosed in early May, with about 15 sites established as the company chases the disease from the northeast to the southern states.
Mesoblast chief medical officer Professor Fred Grossman says the company is carefully choosing hot spots such as Alabama which, as of late May had the no vacancy signs outside its intensive care wards.
The sites are recruiting quite quickly, he says. There is a tremendous interest in this study.
The trial leaders will undertake an interim analysis at 30 days, and when 30 per cent of patients have reached their primary endpoint. At that point the trial can be dumped on futility grounds, or expanded to the control group because it appears to be working.
Remestemcell-L has investigational new drug (IND) status with the US Food and Drug Administration, meaning the company swiftly can initiate trials on patients with very dismal prospects.
Long-suffering Mesoblast investors will recall that the companys shares tumbled 28 per cent in November 2018 after a 159-patient trial of Rexlemestrocel-L (Revascor) for end-stage heart failure did not meet its primary endpoint of weaning patients from left ventricle assist devices (LVADs or heart pumps).
The company claimed the endpoint was set by the independent !!! investigators and was of little real clinical interest. What really mattered was that the trial showed reduced gastrointestinal bleeding by 76 per cent and hospitalisations by 65 per cent.
Investors are now nervously awaiting the first readout of the broader 566-patient chronic heart failure trial across 59 US sites.
Mesoblast targeted patients with class three or four disease, the sickest 15 to 20 per cent of patients who have failed standard-of-care drugs.
Class three patients have a 20 per cent chance of dying within two years while with class four its a case of flip a coin that you will be around in 12 months.
At this stage, Mesoblast retains its heart treatment rights except in China, where it is partnered with Tasly Pharmaceutical.
Mesoblasts phase III back pain trial aimed to enroll 404 patients with lower back pain caused by degenerative disc disease.
The endpoint of the trial, dubbed MPC-06-ID, is an improvement in pain and function over 24 months.
As with the heart trial, results are imminent and its a toss-up as to what release will hit the ASX announcements feed first.
The company is liaising with its global back pain partner Grunenthal GmbH about the clinical protocol for a European phase III confirmatory trial.
In Japan, Mesoblast is partnered with JCR Pharmaceutical for its approved GvHD treatment called Temcell and its off and racing in that smallish but enthusiastic market.
Meanwhile, the company is angling to enter the US market for a similar GvHD treatment, branded Ryoncil.
GvHD afflicts about half of the 30,000 patients annually undergoing allogeneic bone marrow transplant, typically for blood cancers, with their bodies rejecting the alien transplant.
In March, the FDA granted priority review with a September 30 action date, but we might have a good idea of the outcome in August.
Why? Because thats when the FDAs relevant advisory committee meets to vote on the matter and the (virtual) gathering is open to the public.
A date is yet to be set. While advisory committee views are not binding on the FDA, they usually presage the final decision.
If approved, Mesoblast could be selling Ryoncil in the US by the time were carving the Christmas turkey (badly, in the case of your columnist).
Buoyed by the COVID-19 results, Mesoblast in May wasted no time tapping institutional investors for an idle $US90m ($129.6m) in a placement.
Mesoblast already had a healthy cash balance of $US60m.
The raising was struck at $3.20 a share, a modest 7 per cent discount to the prevailing price.
The funds, in the main, will be used to scale-up manufacturing of remestemcell-L and to support the phase III trial, as well as for working capital and general corporate purposes.
The company also has $US67m available through existing financing facilities and partnerships.
Mesoblast reported revenue of $US31.45m for the nine months to March 2020, up 113 per cent. The reported loss narrowed 34 per cent to $US45.3m, reflecting curtailed research and development spend by $US7.5m, or 15 per cent.
The revenue included $US5.9m of JCR royalties from Temcell sales in Japan and milestone revenue of $US25m.
The company stands to pocket up to $US150m of royalties and milestones from Grunenthal prior to any European launch of Revascor.
Successful sales could result in up to $US1bn in milestone payments.
Over the last decade, Mesoblasts ASX shares have traded as high as $9 (October 2011) and as low as $1.03 (December last year).
To the Meso-sceptics the company has promised far too much with limited commercial success, while raising $1bn since listing 16 years ago.
Dare we say that Mesoblast now looks more focused and to be getting somewhere?
When we last covered Mesoblast in March 2019, Professor Itescu said he was 95 per cent certain the company would do what no other Aussie biotech in phase III had done: win FDA drug approval.
Well, Clinuvel has stolen that Aussie first honour, but Mesoblast is well placed to get over the line with a GvHD treatment in the US, which presents a market eight times the size of Japans.
Its certainly rare for a biotech to expect results for three major trials and a key regulatory decision in the space of months.
If the heart and back pain results are definitively positive and the FDA green lights GvHD, the company hits the jackpot. If two or more of them bomb lets not go there.
Your ultra conservative columnist regards the COVID-19 stuff as the icing on the cake with an outside chance of success, especially given the hundreds of other programs in the coronavirus-busting sector.
Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. But he hopes to become proficient in turkey carving by December 25.
This column first appeared in Biotech Daily.
Get the latest Stock & Small Caps news and insights direct to your inbox.
It's free. Unsubscribe whenever your want.
You might be interested in
See the original post here:
Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead
Posted: September 12, 2019 at 1:44 pm
The first commercial product from Hampton Creeks new clean meat production platform will likely be in the avian family, director of cellular agriculture Eitan Fischer told FoodNavigator-USA as the company best known for its work on plant-based proteins unveiled ambitious plans to explore the animal variety.
Fischer was speaking to us after Hampton Creek founder Josh Tetrick posted anarticle on linkedin explaining that producing 'clean' or 'cultured' meat (by culturing cells without raising or slaughtering animals) and plant-based meat/eggs, both stemmed from a desire to find kinder and more sustainable alternatives to industrial animal farming.
His comments came as Dr Eric Schulze, senior scientist at Memphis Meats probably the best-known clean meat company told delegates at the IFT show this week that his company aims to launch premium-priced clean meat products in high-end restaurants in 2019, and more mass market products in grocery stores in 2021.
Poultry will likely be first to market in late 2018, Fischer told us: We believe the first product released commercially will likely be in the avian family.
Longer term, however, the plan is to build a multi-species, multi-product platform spanning the entire range of meat and seafood, he said.
We haven't solved the meat and seafood problem until we are able to make all of these products.
Asked how long Hampton Creek had been working on the technology, and what kinds of scientists were working on the project, he said: We have been working on this for over a year. Many members of our 59-person R&D team are involved, between our molecular team, our analytical chemistry team, our process team, and our product development team.
We also supplemented the significant in-house expertise we had previously with additional, more specific specialists such as scientists with stem cell biology, medicine, and tissue engineering backgrounds.
"We believe that clean meat can be evaluated and regulated within existing regulatory frameworks... Clean meat is a food, not a drug, not a new animal drug or a food additive..." [read more on this at FoodNavigator-USA next week..]
Rebecca Cross, counsel,Davis Wright Tremaine LLP
We think its unlikely that families in Alabama (or anywhere in the world) will consistently choose plant-based alternatives over chicken, beef, pork, and seafood Over the past year, weve started the early work of expanding our platform to solve the technical challenges of scalable clean meat.
With plants providing nutrients for animal cells to grow, we believe we can produce meat and seafood that is over 10x more efficient than the worlds highest volume slaughterhouse.
Imagine choosing between a similarly priced pound of clean high-grade bluefin tuna belly or conventional tilapia from underwater traps. Or clean A5 Kobe beef versus conventional sirloin (corn-fed and confined). Our approach will be transparent and unquestionably safe, free of antibiotics and have a much lower risk of foodborne illness. The right choice will be obvious.
Weve started the process of licensing our discoveries to the worlds largest food manufacturers and, in the years ahead, well do the same with the worlds largest meat and seafood companies.
Josh Tetrick, founder and CEO, Hampton Creek
Fischer would not say what kind of stem cells the company is using, or whether the plan is to first proliferate cells in a stir tank bioreactor and then transfer them to a larger perfusion type bioreactor where they will mature and differentiate in to the different cell types (fat, muscle, connective tissue).
However, he confirmed that, We are building a platform that enables us to produce cells of different types including muscle, fat, and others, in a bioreactor-based process.
As for the go-to-market strategy, he said: We are exploring various options for the initial release but are most focused on how to get the costs down to parity or below current meat prices. We haven't truly solved the meat and seafood problem until we've done so.
The company has not said what it is using as a growth medium (the nutrient-rich bath the cells need to grow) but said its expertise in plant-based products had enabled it to develop a viable vegan alternative to animal serum.
"The entry of a billion-dollar company into the clean meat market sector is a vote of confidence in the technology, and we hope that Hampton Creek will be the first of many major food companies to dive into this incrediblypromisingfield."
Bruce Friedrich, executive director, The Good Food Institute
In a mapping document penned by the Good Food Institute earlier this month, the authors predicted that clean meat would likely come to market in phases, with the first products perhaps hybrids combining clean meat and plant-based meat; followed by ground meat products (nuggets, burgers); and finally those mimicking steaks or chicken breasts, which present significantly greater technical challenges.
The first products that come to market may be hybrid products wherein clean meat is included as a part of plant-based products that essentially require only cell lines, media, and proliferative bioreactors to come to fruition.
They add: The next commercial products will likely be ground meat mimics, where scaffolding can be minimal; more complex structures requiring vascularization or perfusion bioreactors are not necessarily required.
Finally, more structured tissues like those mimicking steaks or chicken breasts will require research and development in all of the areas outlined above. Thus, a consideration of target product(s) should drive the R&D focus.
Speaking at a webinar hosted by the GFI on June 8, Dr Specht added: "I think there's a lot of evidence to suggest that consumers would be interested in hybrid products," citing the success of products already on the market that feature combinations of regular meat and plant-based ingredients, such as mushroom blend burgers and sausages with 40% meat, which are marketing on a health and sustainability platform, and can also be more affordable.
"The phrase 'clean meat' is similar to 'clean energy' in that it immediately communicates important aspects of the technologyboth the environmental benefits and the decrease in food-borne pathogens and drug residues."
Bruce Friedrich, executive director, The Good Food Institute
This Good Food Institute schematic illustrates one conception of the clean meat production process at scale. The first stage is proliferation of the cells, followed by a differentiation and maturation stage where cells are seeded onto scaffolds and allowed to mature into the cell types required for meat.
Clean meat production begins with obtaining cell lines for the desired animal species (eg. chicken, pork, beef) that behave in a predictable way through many generations, while maintaining an unlimited capacity to reproduce/divide (ie. immortalized cell lines).
Next you have to proliferate cells, perhaps in a stir tank bioreactor where you might suspend your cells in the growth medium (both Hampton Creek and Memphis Meats claim to have found viable alternatives to animal serum read more about that HERE ) and stir them and keep them warm.
As for the next stage, where you want to encourage the creation of an organized pattern of muscle, fat, and connective tissue cells, this would probably require seeding onto scaffolding and then differentiating into the various cell types, the stage at which you get real fat cells forming and the muscle cells forming into fibers to give that authentic meaty texture, said Dr Specht.
Here, the scaffolding would need to be something that is subsumed within the final meat product so it would have to be made out of something that is degradable over time, or something edible that would not impact the taste or safety of the final product such as cellulose or collagen, she said.
To accommodate three-dimensional growth, the scaffolds must exhibit porosity for perfusing nutrient media [the nutrients have to be able to reach the cells], she added. Alternatively, they must support vascularization of the tissue itself, i.e., the formation of a network of vessels to allow nutrients to permeate the tissue. Several production methods, including 3D printing and spun-fiber platforms, allow fine-tuning of pore size and microstructures within the scaffold.
"Once you get to the scaffold stage, that area is less explored and has not yet been demonstrated at scale."
Interested in clean meat?
GFI senior scientist Dr Liz Specht will give delegates at FOOD VISION USA 2017 the lowdown on clean meat, while Alex Lorestani will explain how Geltor is producing gelatin without animals. See the latest speaker list HERE .
See the original post here:Hampton Creek to enter clean meat market in 2018: 'We are building a multi-species, multi-product platform' - FoodNavigator-USA.com
Read the original post:
Alabama Stem Cells | Stem Cell TV
Posted: April 20, 2019 at 4:49 pm
Michael S. Beckenstein, M.D. a Birmingham, Alabama, plastic surgeon is the offering the only cosmetic stem cell therapy in Alabama. He first brought this latest therapy to his T3 hair restoration practice and has been successfully using this to treat hair loss in men and women. Stem cell therapy is gaining popularity in all fields of medicine especially orthopedics, cardiology, and regenerative medicine. Stem cells are being used to grow new cells and tissue like heart muscle cartilage, and other cells. Stem cells can build or regenerate new cells and tissues. Injecting them in and around surgical sites, such as tendon and ligament repairs helps create stronger repairs.
Stem cells can be found in bone marrow and fatty tissue. These cells can be easily harvested through needle aspiration. It is far easier and less painful to take these cells from fatty areas. we are well versed in performing liposuction, and how we obtain this fat specimens are ridiculously easy states Dr. Beckenstein. We use tiny cannulas, just as we do for liposuction, but real small, for the amount of tissue we take. We need only a minimal amount to obtain the cells we need. By using a highly specialized process, using incredible technology, true stem cells are concentrated into an injectable form. In order to obtain real stem cells, an amazing, staged process is needed and we use the Healeon technology, which is safe, fast, and enable us to yield 99% viable cells. Adds Dr. Beckenstein. these are real cells, there are many practices, and products that say they are stem cells, yet they are not! The patient must ask the right questions about this and obtain proof about what they are receiving.
Stem cells can be injected into the scalp to regenerate hair follicles allowing them to create thicker hair shafts, which thickens ones hair. T3 Hair Restoration is the first to introduce this to the southeast region and is seeing good success with this therapy. Stem cells can also be effective in regeneration of aging tissues such as skin and the underlying soft tissue. Injecting stem cells into these areas can create a more youthful, healthy appearance. while nothing is the fountain of youth Dr. Beckenstein cautions, this therapy can yield nice improvements for women and menalike.
For those seeking information on this exciting, revolutionary therapy for Alabama hair restoration or aging skin, please visit us online at http://www.msbmd.com or t3hair.net, or contact us at 205-933-9322?1-866-MSBMD77.
See the original post:
Only Cosmetic Stem Cell Therapy in Alabama - msbmd.com
Posted: March 23, 2019 at 7:42 pm
The doctors affiliated with National Stem Cell Centers in Houston, TX specialize in harvesting tissue and having the cells processed at our registered tissue processing lab.
The physicians follow compliant protocols where the tissue is not manipulated and there is no tissue or cell expansion.
We also do not use enzymes as per FDA guidelines.
Stem cell procedures hold great potential for the management of joint pain, arthritis, hair loss, cosmetic and other disorders as well as auto-immune, renal, and neurological disorders.
There are various types of stem cells, particularly as they pertain to potential procedures, including umbilical cord cells, adipose (fat-derived), amniotic cells, placenta, bone marrow, exosomes, and others.
The physician will go over your options during your complimentary consultation.
Dr. Baker is a general surgeon by training and a native of Northeast Texas.
His general surgery training makes him uniquely qualified as an excellent stem cell physician.
After graduating from the University of Arkansas with the highest honors,
Dr. Baker attended the University of Texas Medical School at Houston where he was awarded the prestigious Parents and Alumni Scholarship.
During medical school, Dr. Baker was selected to participate in the competitive summer research program and remained active in research throughout medical school.
Following medical school and research commitments, Dr. Baker moved to Phoenix, Arizona where he began his surgical education. It was in the Scottsdale area that Dr. Baker began to hone his artistic eye for body sculpting. Dr. Baker also garnered broad experience in regenerative medicine around this time as aesthetic improvement and restorative complementary medicine techniques often go hand in hand.
In the six years since Dr. Baker has treated thousands of cosmetic patients and a near equal quantity of functional medicine patients. He strives to remain on the cutting edge through continued education and a meticulous attention to detail for all of his patients with a willingness to think outside the box and look for options that traditional medicine might otherwise not consider.
Dr. Thiele is a General Surgeon with five years of training in general surgery.
He is a Diplomate of the American Board of Management Wound which has helped hone his hair transplant techniques including FUT, graft harvesting, recipient site making, anesthesia, pain management and wound healing.
He has worked as a Physician at the East Texas Medical Center and Mother Francis Hospital in Tyler, and served as a Physician with VOHRA Would Physicians, TeleHealth, Murdock & Applegate Recovery.
He attended medical school at the University of Texas in Galveston and trained at Mercer University in Georgia and Charleston Area Medical Center in W. Virginia.
Dr. Thiele performs the FUT as well as FUE procedures at MAXIM Hair Restoration in Houston and Dallas, Texas.
Dr. Christopher Hankins is a plastic surgeon who trained on stem cell therapy with the world renowned regenerative surgeon Dr. David A. Mayer in New York City.
Dr. Hankins also specializes in face, breast, and body aesthetic surgery. He also has advanced training in hand surgery, breast reconstruction after cancer, and other reconstructive surgical procedures. This training enables him to perform stem cell harvests with relative ease, producing a great yield of tissue for processing.
Dr. Hankins completed five plastic surgery fellowships in the U.S. and U.K. including the Baylor College of Medicine, and a Hand Surgery fellowship at the University of Alabama at Birmingham.
Dr. Hankins completed his M.D. degree from the University of Texas Medical Branch at Galveston.
Dr. Hankins served as the Medical Director of the Wound Care Center at the Lake Jackson Hospital. He is actively involved in study and clinical application of anti-aging medicine.
Dr. Hankins has authored 19 manuscripts in peer-reviewed journals, and serves on the editorial boards of four medical journals. He has been a presenter on a variety of topics worldwide.
Dr. Hankins has participated in plastic surgery medical missions to Peru, Bolivia, and Pakistan where he performed a number of surgical procedures on disadvantaged children and adults. He sits on the Boards of charitable foundations for children.
Schedule your complimentary stem cell therapy consultation today with one of our affiliated physicians in Houston, Texas, by calling (802) 278-5098 or submit the Contact Form on this page.
This location serves Houston, Sugarland, Katy, Heights, Austin, San Antonio and all of Texas.
Address:6910 Bellaire Blvd.,Building 9Houston, Texas 77074
See the original post:
Stem Cell Therapy in Houston, TX | National Stem Cell Centers
Posted: March 6, 2019 at 7:42 pm
First in the River Region Serving Pain Patients with Cutting Edge Interventional Pain Management CareSince 1993.
The mission of Central Alabama Pain Management Center is to provide compassionate cutting edge care to the River Region citizens. In that vain, CAPMC is thrilled to announce the addition of Orthobiological Regenerative Medicine procedures. We now use your Platelets and Stem Cells to promote natural healing of your degenerative Joints and Discs of your Spine.
Call us to schedule an evaluation to determine if you are a candidate for Regenerative Interventional Care.
Generally our patients are referred to our practice. We do, however, accept self referral in some instances.
Your evaluation and treatment begins with our physicians face to facevisit. We do not use nurse practitioners or physicians assistants to perform your evaluation. At that time of your examinationyour treatment plan will be determined for you.
Services offered include the following:
Medication optimization and management
Interventional Nerve Blocks ranging from Epidurals,transforaminals nerve root blocks, facet joint blocks, large joint injections andRadiofrequency Neuroablation
Dorsal Column Stimulator Trials, surgical implantation, and reprogramming service are available
Proliferative (Prolo) Therapy stimulates Ligament and Tendon healing
Regenerative Medicine services range for Platelet Rich Plasma (PRP) injections to Stem Cell harvest and re-implantationfor management ofdegenerative joints and discs.
All though we no longer implant Intrathecal Pain Pumps, we do continue to manage our previous implants.
Here is the original post:
Central Alabama Pain Management Center Established 1993
Posted: January 4, 2019 at 5:50 pm
Stem cell therapy has actually become a popular debate in the worldwide medical scene. This highly controversial treatment has received mixed viewpoints from various stakeholders in the healthcare market and has likewise attracted the attention of politicians, religious leaders and the general population at large. Stem cell treatment is thought about a revolutionary treatment for people experiencing a large range of degenerative conditions. Some typical concerns regarding this therapy are responded to listed below.
Stem cells can be described as blank state or non-specialized cells that have the ability to become specialized cells in the body such as bone, muscle, nerve or organ cells. This suggests that these unique cells can be used to regrow or establish a vast array of broken cells and tissues in the body. Stem cell therapy is therefore a treatment that targets at accomplishing tissue regrowth and can be utilized to treat health conditions and health problems such as osteoarthritis, degenerative disc illness, spine injury, muscular degeneration, motor nerve cell illness, ALS, Parkinsons, cardiovascular disease and much more.
Stem cells can be extracted from a young embryo after conception. These stem cells are commonly described as embryonic stem cells. After the stem cells are extracted from the embryo, the embryo is terminated. This is generally one of the significant causes of controversy in the field of stem cell research study. Many individuals suggest that termination of an embryo is dishonest and unacceptable.
Stem cells can still be gotten through other ways as they can be found in the blood, bone marrow and umbilical cables of adult people. Normal body cells can also be reverse-engineered to become stem cells that have actually restricted abilities.
Being a treatment that is still under studio, stem cell therapy has actually not been totally accepted as a feasible treatment choice for the above discussed health conditions and illnesses. A lot of research is currently being carried out by scientists and medical specialists in numerous parts of the world to make this treatment sensible and effective. There are however different restrictions imposed by federal governments on research including embryonic stem cells.
Presently, there havent been lots of case studies carried out for this type of treatment. However, with the few case studies that have actually been carried out, among the major concerns that has been raised is the increase in a clients risk of establishing cancer. Cancer is caused by the quick multiplication of cells that tend not to die so easily. Stem cells have actually been connected with comparable growth elements that may result in formation of tumors and other cancerous cells in clients.
New research study has actually nevertheless shown promise as researchers target at developing stem cells that do not form into tumors in later treatment stages. These stem cells can therefore effectively transform into other types of specialized cells. This treatment is for that reason worth investigating into as numerous clients can gain from this innovative treatment.
Find a stem cell doctor in Mobile AL 36607
Read more from the original source:
Stem Cell Mobile Alabama 36607
Posted: August 30, 2018 at 4:50 pm
Stem cell treatment has become a popular debate in the global medical scene. This extremely questionable treatment has gotten mixed viewpoints from numerous stakeholders in the healthcare industry and has actually also attracted the interest of politicians, spiritual leaders and the general population at large. Stem cell therapy is considered a revolutionary treatment for people dealing with a wide variety of degenerative conditions. Some common questions concerning this treatment are answered listed below.
Stem cells can be referred to as blank state or non-specialized cells that have the capability to become specific cells in the body such as bone, muscle, nerve or organ cells. This implies that these special cells can be utilized to regrow or develop a vast array of broken cells and tissues in the body. Stem cell therapy is for that reason a treatment that aims at achieving tissue regeneration and can be utilized to treat health conditions and health problems such as osteoarthritis, degenerative disc disease, spine injury, muscular degeneration, motor nerve cell illness, ALS, Parkinsons, heart problem and much more.
Stem cells can be extracted from a young embryo after conception. These stem cells are commonly referred to as embryonic stem cells. After the stem cells are extracted from the embryo, the embryo is terminated. This is generally among the major causes of debate in the field of stem cell research. Lots of people suggest that termination of an embryo is dishonest and undesirable.
Stem cells can still be gotten through other methods as they can be found in the blood, bone marrow and umbilical cables of adult humans. Normal body cells can also be reverse-engineered to become stem cells that have restricted capabilities.
Being a treatment that is still under research, stem cell treatment has not been totally accepted as a sensible treatment option for the above discussed health conditions and illnesses. A great deal of research study is presently being performed by researchers and medical professionals in numerous parts of the world to make this treatment viable and efficient. There are however various restrictions enforced by federal governments on studio involving embryonic stem cells.
Presently, there have not been numerous case studies carried out for this kind of treatment. Nevertheless, with the few case studies that have been carried out, one of the major issues that has actually been raised is the boost in a patients threat of establishing cancer. Cancer is brought on by the quick reproduction of cells that tend not to die so easily. Stem cells have been connected with comparable development aspects that may cause formation of tumors and other cancerous cells in clients.
New research has actually nevertheless shown guarantee as researchers focus on establishing stem cells that do not form into growths in later treatment stages. These stem cells can therefore successfully change into other kinds of specialized cells. This therapy is for that reason worth researching into as many clients can benefit from this innovative treatment.
Need a stem cell therapy in Birmingham AL 35282
The rest is here:
Stem Cell Birmingham Alabama 35282
Posted: July 24, 2018 at 2:42 am
Search by Last Name
Search by Last NameAhnAl-MehdiAlexeyevAlvarezArrietaAudiaAylingBalczonBallardBarringtonBauerBogarCioffiCioffiCohenDanielDarbinDowneyFaganFieldsFoutyFrancisGardGassmanGebbGerthofferGilbertGillespieHonkanenKayesKimLangleyLauschLeClaireLeDouxLimLinLincolnMcMurtryMigaudOakesOkaOlsonPallePannellParkerPastukhPiazzaPolskiPrakashRachekRaynerRichRichterRocconiRuchkoSaynerScaliciScammellSchafferSchulerShokolenkoSinghSinghSobolSolodushkoSosnowskiStevensStradaTanTaylorTownsleyWagnerWangWeberWilsonWinklerWoodWuXinZha
Research Interests Access to health care Actin cytoskeleton remodeling and the ARP 2/3 complex in cancer cell metastasis Anticancer activity of nonsteroidal anti-inflammatory drugs Autoimmunity Bacterial Physiology and Genetics Basic mechanisms and clinical pharmacology of pulmonary arterial hypertension Calcium signaling and autoantibodies in pulmonary endothelial barrier disruption Cancer drug discovery and development Cancer metastasis Cancer prevention through behavioral intervention Cancer progression and metastasis Cancer stem cells Cancer survivorship studies Cancers that are diagnosed late stage such as ovarian and pancreatic cancer Carcinogenesis and drug resistance Cardiac Physiology Cell cycle regulation and DNA replication Cellular mechanisms of DNA repair and metabolism Cellular metabolism and its relevance to health through balanced and informed vitamin supplementation Chemokine signaling in cancer progression, angiogenesis and metastasis Childhood, adolescent, and young adult cancers Clinical/preclinical studies in vaccine development Collateral Vessels Colorectal cancer Convergent role of enzymes and pathways in response to environmental Geno toxins and chemotherapy Developing new screening methods for issues such as complications of pregnancy DNA damage response and repair pathways (special focus on Fanconi anemia pathway and homologous recombination) DNA topoisomerases and their inhibitors Emerging viruses Endometrial Cancer Enzyme Binding and Kinetics Flow Cytometry Fostering health care networks Gene regulation Glycochemistry and pulmonary glycocalyx Health communications Health disparities Hematopathology Herpes simplex Eye Infections HIV-1 Host-Pathogen Interactions Identification of novel targets for cancer therapy Identifying proteomic biomarkers using proteomic and glycomic methods for the early detection and monitoring of cancer Immune Regulation Inflammation Influenza viruses Ischemic Preconditioning Laboratory of Infectious Diseases Lung injury and repair Mechanism of base excision repair Melanoma and non-melanoma skin cancer Metabolism and cancer Methods to improve the test for prostate cancer MicroRNA and cancer MicroRNAs in cancer Mitochondrial Disease and Cancer Molecular cancer therapeutics (identification of novel drug targets and therapeutics development) Molecular diagnosis, prognosis and sub-classification of cancer Molecular libraries screening and cellular imaging Natural products as cancer prevention and therapy agents Novel chemical entities as putatives anti-cancer lead compounds Obligate Intracellular Parasitism Ovarian Cancer Oxidative DNA Damage and Repair PARP and NAD+ metabolism in human cells Phosphodiesterases, cyclic GMP signaling, and apoptosis Posttranslational modifications (special focus on ubiquitin ligases and their role in DNA damage response and repair) Progression of pulmonary arterial hypertension (PAH) Pulmonary Immunology and Infections Regulation of transcription and RNA splicing in cancer stem cells Response of DNA repair pathways to damage induced by exposure to endocrine disrupting chemicals (EDCs) Role of cAMP-phosphodiesterases (PDEs) in the temporal and spatial control of cAMP signals Roles of non-coding RNAs in cancer development and progression Select Agents and Biodefense Sepsis SON-mediated constitutive/alternative RNA splicing and cancer Structural Biology including Macromolecular X-ray Crystallography and Small Angle X-ray Scattering Targeted cancer therapy Telehealth Therapeutic resistance Therapeutic resistance in cancer Tumor-stromal interactions Vaccine Development Vascular remodeling in lung circulation and its impact on blood flow pattering Viral transmission and pathogenesis Vitamin B3 (Niacin) metabolism and its impact on disease management, treatment and prevention
Read more here:
USA College of Medicine - University of South Alabama ...
Posted: August 24, 2017 at 5:47 am
Neuro-oncologists from the University of Alabama at Birmingham and Jiaotong University have found a new treatment that inhibits glioblastoma growth.
Researchers led by the University of Alabama at Birmingham's Dr. Ichiro Nakano and the Xi'an Jiaotong University's Dr. Maode Wang found a way glioma stem cells are maintained inside molecules, and they experimented to see it could be used in treating glioblastoma. The scientists created a small molecule inhibitor that they tested to see if could be used as a therapeutic target in glioblastoma.
The group conducted the test after it found that an another inhibitor of cancers that were past early stages, called OTS167, did not work in treating glioblastoma in another experiment.
Nakano's research facility unveiled that NEK2, kinase enzyme, grew following OTS167 treatment. Researchers then built a different inhibitor, CMP3a, via computer to slow growth in pre-clinical models. They experimented with CMP3a, which revealed that the CMP3a prevented glioblastoma from getting bigger in mice.
When the CMP3a was used with radiation, researchers unveiled that the combination kept glioblastoma from getting bigger in culture.
See original here:
Researchers find new glioblastoma inhibitor - Patient Daily
Posted: August 12, 2017 at 6:44 am
Scientists have created an electronic wafer that reprogrammed damaged skin cells on a mouse's leg to grow new blood vessels and help a wound heal.
One day, creator Chandan Sen hopes, it could be used to be used to treat wounds on humans. But that day is a long way off as are many other regeneration technologies in the works. Like Sen, some scientists have begun trying to directly reprogram one cell type into another for healing, while others are attempting to build organs or tissues from stem cells and organ-shaped scaffolding.
But other scientists have greeted Sen's mouse experiment, published in Nature Nanotechnology on Monday, with extreme skepticism. "My impression is that there's a lot of hyperbole here," says Sean Morrison, a stem cell researcher at the University of Texas Southwestern Medical Center. "The idea you can [reprogram] a limited number of cells in the skin and improve blood flow to an entire limb I think it's a pretty fantastic claim. I find it hard to believe."
When the device is placed on live skin and activated, it sends a small electrical pulse onto the skin cells' membrane, which opens a tiny window on the cell surface. "It's about 2 percent of the cell membrane," says Sen, who is a researcher in regenerative medicine at Ohio State University. Then, using a microscopic chute, the chip shoots new genetic code through that window and into the cell where it can begin reprogramming the cell for a new fate.
Sen says the whole process takes less than 0.1 seconds and can reprogram the cells resting underneath the device, which is about the size of a big toenail. The best part is that it's able to successfully deliver its genetic payload almost 100 percent of the time, he says. "No other gene delivery technique can deliver over 98 percent efficiency. That is our triumph."
To test the device's healing capabilities, Sen and his colleagues took a few mice with damaged leg arteries and placed the chip on the skin near the damaged artery. That reprogrammed a centimeter or two of skin to turn into blood vessel cells. Sen says the cells that received the reprogramming genes actually started replicating the reprogramming code that the researchers originally inserted in the chip, repackaging it and sending it out to other nearby cells. And that initiated the growth of a new network of blood vessels in the leg that replaced the function of the original, damaged artery, the researchers say. "Not only did we make new cells, but those cells reorganized to make functional blood vessels that plumb with the existing vasculature and carry blood," Sen says. That was enough for the leg to fully recover. Injured mice that didn't get the chip never healed.
When the researchers used the chip on healthy legs, no new blood vessels formed. Sen says because injured mouse legs were was able to incorporate the chip's reprogramming code into the ongoing attempt to heal.
That idea hasn't quite been accepted by other researchers, however. "It's just a hand waving argument," Morrison says. "It could be true, but there's no evidence that reprogramming works differently in an injured tissue versus a non-injured tissue."
What's more, the role of exosomes, the vesicles that supposedly transmit the reprogramming command to other cells, has been contentious in medical science. "There are all manners of claims of these vesicles. It's not clear what these things are, and if it's a real biological process or if it's debris," Morrison says. "In my lab, we would want to do a lot more characterization of these exosomes before we make any claims like this."
Sen says that the theory that introduced reprogramming code from the chip or any other gene delivery method does need more work, but he isn't deterred by the criticism. "This clearly is a new conceptual development, and skepticism is understandable," he says. But he is steadfast in his confidence about the role of reprogrammed exosomes. When the researchers extracted the vesicles and injected them into skin cells in the lab, Sen says those cells converted into blood vessel cells in the petri dish. "I believe this is definitive evidence supporting that [these exosomes] may induce cell conversion."
Even if the device works as well as Sen and his colleagues hope it does, they only tested it on mice. Repairing deeper injuries, like vital organ damage, would also require inserting the chip into the body to reach the wound site. It has a long way to go before it can ever be considered for use on humans. Right now, scientists can only directly reprogram adult cells into a limited selection of other cell types like muscle, neurons and blood vessel cells. It'll be many years before scientists understand how to reprogram one cell type to become part of any of our other, many tissues.
Still, Morrison says the chip is an interesting bit of technology. "It's a cool idea, being able to release [genetic code] through nano channels," he says. "There may be applications where that's advantageous in some way in the future."